EFMH
ALNY icon

E Fund Management (HK)’s Alnylam Pharmaceuticals ALNY Stock Holding History

E Fund Management (HK)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Buy
778
+247
+47% +$74.5K 0.08% 145
2026
Q1 		$176K Buy
531
+142
+37% +$48.3K 0.08% 129
2025
Q4 		$132K Buy
+389
New +$172K 0.04% 148

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

E Fund Management (HK)'s ALNY Position: Q2 2026 in Review

E Fund Management (HK) increased its Alnylam Pharmaceuticals (ALNY) stake by 47% in Q2 2026, buying an estimated $74.5K and bringing the position to 778 shares worth $234K. The position accounts for 0.08% of the portfolio, ranked #145.

E Fund Management (HK) first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • E Fund Management (HK) held 778 shares of Alnylam Pharmaceuticals worth $234K as of Q2 2026.
  • E Fund Management (HK) bought 247 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $74.5K.
  • Alnylam Pharmaceuticals made up 0.08% of E Fund Management (HK)'s portfolio in Q2 2026, its #145 holding.
  • E Fund Management (HK) first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.